

APR 24 2006

PTO/SB/08A(06-03)
 Approved for use through 07/31/2006, OMB 0651-0031
 US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A SBAUSCH

Sheet 1 of 1

Attorney Docket No: SGL-2020-UT

US PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SB	A1.	4,889,818	12/26/1989	GELFAND and STOFFEL	
	A2.	5,648,482	07/15/1997	MEYER	
	A3.	6,077,664	06/20/2000	SLATER and HUANG	
	A4.	6,140,054	10/31/2000	WITTEWER and BERNARD	
	A5.	5,912,120	06/15/1999	Goldstein et al	
SB	A6.	5,786,191	07/28/1998	Goldstein et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
SB	A7.	WO 00/12757	03/09/2000	Hauzenberger		
	A8.	WO-91/10745	07/25/1991	WOLF and MILES		
	A9.	WO-01/55432	08/02/2001	RAIMUNDO and ZANGER		
	A10.	EP0463395 B1	05/14/1997	MEYER		
	A11.	EP0759476 A1	02/26/1997	KAMATAKI		
	A12.	WO-95/30766	11/16/1995	Goldstein et al		
SB	A13.	GB 2371091	07/17/2002	Williams et al		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SB	A14.	CHURCHILL and DOERGE, Genetics, 138:963-971 (1994)	
	A15.	LUNDQVIST et al., Gene, 226:327-338 (1999)	
	A16.	RAIMUNDO et al., Eur. J. Clin. Pharmacol., 55:A5 (1999)	
	A17.	RAIMUNDO et al., Pharmacogenetics, 10:577-581 (2000)	
	A18.	KIMURA et al., Am. J. Hum. Genet., 45(6):889-904 (1989)	
	A19.	ROMKES et al., Biochemistry, 30(13):3247-3253 (1991)	
SB	A20.	MAREZ et al., Pharmacogenetics, 7:193-202 (1997)	

EXAMINER /Sarae Bausch/

DATE CONSIDERED

06/19/2006

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

APR 24 2006

PTO/SB/08A(08-03)
 Approved for use through 07/31/2006. OMB 0651-0031
 US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A. <i>S Bausch</i>

Sheet 2 of 2

Attorney Docket No: SGL-2020-UT

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SB ↓	A21.	SACHSE et al., Am. J. Hum. Genet., 60:284-295 (1997)	
	A22.	Gaedigk et al., Clinical Chemistry, 49(6):1008-1011 (2003)	
	A23.	RAIMUNDO et al., Clinical Pharmacology and Therapeutics, 76(2):128-138 (2004)	
	A24.	Soyama et al, Drug Metab. Pharmacokin., 19(4):snp19(313)-snp25(319) 2004	
	A25.	Yamazaki et al., Drug Metab. Pharmacokin., 18(4):snp26(269)-snp28(271) 2003	
	A26.	Lovlie et al., Pharmacogenetics, 11(1):45-55 (2001)	
	A27.	Karam et al., Drug Metabolism and Disposition, 24(10):1081-1087 (1996)	
	A28.	EMBL Database accession no. AR071577	
	A29.	Kim et al., Clinical Pharmacology and Therapeutics, MOSBY year book 69(2):39 (2001)	
	A30.	Excoffier and Slatkin, Mol. Biol. Evol., 12(5):921-927 (1995)	
	A31.	Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.imm.ki.se/cypalleles/	
	A32.	Johannson et al., Molecular Pharmacology, 46:452-459 (1994)	
	A33.	Daly et al., Pharmacogenetics, 6(3):193-201 (1996)	
	A34.	Zanger et al., Pharmacogenetics 11(7):573-585 (2001)	
SB	A35.		

EXAMINER

/Sarae Bausch/

DATE CONSIDERED

06/19/2006

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached